Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Oct 1;215(10):2567–2585. doi: 10.1084/jem.20180628

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Hernandez et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 5. — Crippled control of IAV and other viral infections in IRF9-deficient cells. (A) IAV titers in F-SV40 unstimulated (left) or pretreated (right) with 1,000 U/ml IFN-α2 for 16 h, followed by infection with (A/H1N1/CA/2009) IAV at MOI = 1. Mean ± SD (n = 3) is shown. Cells from three healthy controls were included (C1, C2, and C3), as well as those from the IRF9-deficient patient (IRF9^−/−), her mother (IRF9^+/−), and STAT1-deficient (STAT1^−/−), STAT2-deficient (STAT2^−/−), and IRF7-deficient (IRF7^−/−) patients. Four independent experiments (mean ± SD) are shown. (B) VSV titers in F-SV40 cells unstimulated (left) or pretreated (right) with 1,000 U/ml IFN-α2 for 16 h, followed by infection with VSV at MOI = 3. Four independent experiments (mean ± SD) are shown. (C) IAV titers in stably transfected F-SV40 cells unstimulated (left) or pretreated (right) with 1,000 U/ml IFN-α2 for 16 h, followed by infection with IAV at MOI = 1. Cells were from a healthy control (C1), a STAT1-deficient patient (STAT1^−/−), P (IRF9^−/−), and P’s cells stably transfected with luciferase or WT IRF9 (gray), variants reported to be loss-of-function in in vitro assays (green), variants found in-house (blue), or the patient’s variant (red). Three independent experiments (mean ± SD) are shown. (D) VSV titers in stably transfected F-SV40 cells unstimulated (left) or pretreated (right) with 1,000 U/ml IFN-α2 for 16 h, followed by infection with VSV at MOI = 3. Four independent experiments (mean ± SD) are shown. (E) Percentage of RSV-infected (GFP⁺) F-SV40 cells at 24 and 48 h after infection. Cells from three healthy controls were included (C1, C4, and C5, black), as well as those from the IRF9-deficient patient (IRF9^−/−, red), and cells from STAT1-deficient (STAT1^−/−), STAT2-deficient (STAT2^−/−), and IRF7-deficient (IRF7^−/−) patients. Three independent experiments (mean ± SD) are shown. (F) Mean fluorescence intensity (MFI) of RSV-infected (GFP⁺) F-SV40 cells at 24 and 48 h after infection. Three independent experiments (mean ± SD) are shown. (G) Percentage of PIV-infected (GFP⁺) F-SV40 cells at 24 and 48 h after infection. Three independent experiments (mean ± SD) are shown. (H) MFI of PIV-infected (GFP⁺) F-SV40 cells at 24 and 48 h after infection. Three independent experiments (mean ± SD) are shown. MFI of GFP⁺ cells in individual samples were normalized to the averaged MFI of the three healthy controls at 24 h after infection in F and H.